The impact of optimal medical therapy on patients with recurrent acute myocardial infarction: Subanalysis from the BleeMACS study
- 1 November 2020
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 318, 1-6
Abstract
No abstract availableKeywords
Funding Information
- Capital Health Research and Development
This publication has 32 references indexed in Scilit:
- Acute myocardial infarctionThe Lancet, 2017
- BleeMACSJournal of Cardiovascular Medicine, 2016
- National Trends in Recurrent AMI Hospitalizations 1 Year After Acute Myocardial Infarction in Medicare Beneficiaries: 1999–2010Journal of the American Heart Association, 2014
- Incidence, Predictors, and Implications of Reinfarction After Primary Percutaneous Coronary Intervention in ST-Segment–Elevation Myocardial InfarctionCirculation: Cardiovascular Interventions, 2014
- Predictors and Prognostic Impact of Recurrent Myocardial Infarction in Patients with Left Ventricular Dysfunction, Heart Failure, or Both Following a First Myocardial InfarctionEuropean Journal of Heart Failure, 2011
- The effect of optimal medical therapy on 1-year mortality after acute myocardial infarctionHeart, 2010
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trialThe Lancet, 2009
- A Prior Myocardial Infarction: How Does it Affect Management and Outcomes in Recurrent Acute Coronary Syndromes?Clinical Cardiology, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007